Biodesix, a diagnostic company specializing in cancer and lung disease tests, reported first-quarter 2026 revenues of $25.6 million with ongoing net losses reflecting investments in sales and R&D. Its business model revolves around proprietary diagnostic tests including the Nodify CDT platform acquired from Freenome, combined with a U.S.-based direct sales force and biopharma collaborations. While the company benefits from regulatory clearances and payer coverage, it faces risks from reimbursement shifts, supply chain dependencies, and competition. Growth hinges on expanding market acceptance among providers and payers, scaling sales capabilities, and advancing clinical trial support services.